Pfizer, Inc. (NYSE:PFE) is Schwab Charles Investment Management Inc.’s 6th Largest Position
Schwab Charles Investment Management Inc. increased its stake in shares of Pfizer, Inc. (NYSE:PFE) by 1.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 31,260,823 shares of the biopharmaceutical company’s stock after buying an additional 377,404 shares during the period. Pfizer accounts for approximately 1.1% of Schwab Charles Investment Management Inc.’s portfolio, making the stock its 6th largest position. Schwab Charles Investment Management Inc.’s holdings in Pfizer were worth $1,069,433,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of PFE. Fiera Capital Corp raised its position in shares of Pfizer by 3.4% in the fourth quarter. Fiera Capital Corp now owns 104,800 shares of the biopharmaceutical company’s stock valued at $3,404,000 after buying an additional 3,432 shares during the last quarter. Levin Capital Strategies L.P. raised its position in shares of Pfizer by 6.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 8,312,581 shares of the biopharmaceutical company’s stock valued at $269,993,000 after buying an additional 474,404 shares during the last quarter. Intellectus Partners LLC acquired a new position in shares of Pfizer during the fourth quarter valued at $1,296,000. Moloney Securities Asset Management LLC acquired a new position in shares of Pfizer during the fourth quarter valued at $809,000. Finally, Glassman Wealth Services raised its position in shares of Pfizer by 1.7% in the fourth quarter. Glassman Wealth Services now owns 9,605 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 159 shares during the last quarter. 70.10% of the stock is owned by hedge funds and other institutional investors.
Shares of Pfizer, Inc. (NYSE PFE) traded down 0.09% during mid-day trading on Thursday, hitting $33.42. The stock had a trading volume of 2,423,147 shares. The stock has a market cap of $199.45 billion, a P/E ratio of 24.45 and a beta of 1.00. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.38. The company’s 50 day moving average price is $33.44 and its 200 day moving average price is $33.30.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The firm’s revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.64 EPS. Equities research analysts predict that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be given a $0.32 dividend. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.83%. Pfizer’s payout ratio is currently 94.12%.
PFE has been the subject of several analyst reports. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets upgraded Pfizer from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG reiterated a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a research report on Monday, July 31st. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Finally, Jefferies Group LLC reiterated a “neutral” rating and issued a $35.00 price objective (up from $34.00) on shares of Pfizer in a research report on Thursday, April 13th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $37.77.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.